Minerva Neurosciences (NASDAQ:NERV) Stock Price Passes Above 50 Day Moving Average – Should You Sell?

Minerva Neurosciences, Inc (NASDAQ:NERV) shares crossed above its 50-day moving average during trading on Thursday . The stock has a 50-day moving average of $2.13 and traded as high as $2.15. Minerva Neurosciences shares last traded at $2.08, with a volume of 5,496 shares changing hands.

Minerva Neurosciences Stock Down 0.9%

The company has a market capitalization of $14.55 million, a PE ratio of 1.41 and a beta of -0.30. The stock has a 50-day moving average of $2.13 and a 200 day moving average of $1.84.

Minerva Neurosciences (NASDAQ:NERV) last issued its quarterly earnings results on Thursday, August 14th. The biopharmaceutical company reported ($0.43) EPS for the quarter, beating analysts’ consensus estimates of ($0.95) by $0.52. Equities analysts forecast that Minerva Neurosciences, Inc will post -0.3 EPS for the current fiscal year.

Institutional Trading of Minerva Neurosciences

An institutional investor recently bought a new position in Minerva Neurosciences stock. Apella Capital LLC purchased a new stake in shares of Minerva Neurosciences, Inc (NASDAQ:NERV) in the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm purchased 20,625 shares of the biopharmaceutical company’s stock, valued at approximately $35,000. Apella Capital LLC owned about 0.29% of Minerva Neurosciences at the end of the most recent quarter. 34.56% of the stock is currently owned by hedge funds and other institutional investors.

Minerva Neurosciences Company Profile

Minerva Neurosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders.